Akèy › Kansè Vezik ki pa envazif miskilè › Texas › Dallas
Etid klinik pou Kansè Vezik ki pa envazif miskilè nan Dallas, TX
10 etid pou Kansè Vezik ki pa envazif miskilè ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ap rekriteFaz 2
- Urology Clinics of North Texas, Dallas
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Ap rekriteFaz 1
- Cancer Center Outpatient Building, Dallas
- The University of Texas Southwestern Medical Center, Dallas
- UT Southwestern Medical Center - West Campus Building, Dallas
- ak 2 plis
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
Ap rekriteEtid obsèvasyon
- UT Southwestern Medical Center, Dallas
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Ap rekriteFaz 2
- UT Southwestern Medical Center, Dallas
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Ap rekriteEtid obsèvasyon
- University of Texas Southwestern Medical Center, Dallas
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- University of Texas Southwestern, Dallas
- Texas Oncology, P.A, Dallas
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Ap rekriteFaz 1/2
- UT Southwestern Medical Center, Dallas
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
Ap rekriteEtid obsèvasyon
- UT Southwestern Medical Center, Dallas
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Ap rekriteFaz 1/2
- University of Texas Southwestern Medical Center, Dallas
Blue Light Cystoscopy With Cysview® Registry
Ap rekriteEtid obsèvasyon
- UT Southwestern, Dallas
Etid Kansè Vezik ki pa envazif miskilè nan lòt vil
- Columbus, OH10 etid
- New York City, NY10 etid
- Myrtle Beach, SC9 etid
- Edison, NJ9 etid
- Baltimore, MD8 etid
- Syracuse, NY8 etid
- Nashville, TN8 etid
- Houston, TX7 etid
- Indianapolis, IN7 etid
- Philadelphia, PA7 etid
- Birmingham, AL7 etid
- Atlanta, GA7 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè poumon27 etid
- Kansè vejik27 etid
- Kansè Endomèt24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.